STOCK TITAN

Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported that director Richard Ronald received equity awards as part of his board compensation. He was granted 25,344 restricted stock units, each representing one share of common stock upon vesting, for Board and Committee service.

He also received 11,296 stock options with an exercise price of $7.99 per share, expiring in 2033. Both the RSUs and options vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board. After these grants, he directly holds 123,761 common shares.

Positive

  • None.

Negative

  • None.
Insider Richard Ronald
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 11,296 $0.00 --
Grant/Award Common Stock 25,344 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 11,296 shares (Direct, null); Common Stock — 123,761 shares (Direct, null)
Footnotes (1)
  1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
RSU grant size 25,344 RSUs Annual equity grant for Board and Committee service
Stock options granted 11,296 options Stock Option (Right to Buy) tied to common stock
Option exercise price $7.99 per share Exercise price for newly granted stock options
Shares held after grant 123,761 shares Director’s direct common stock holdings following RSU grant
Option expiration 2033-04-30 Expiration date for the granted stock options
Director comp allocation 25% to options Portion of non-employee director compensation used to size option grant
restricted stock units ("RSUs") financial
"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title of Common Stock"
Stock Incentive Plan financial
"granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
Annual Grant Vesting Date financial
"shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date")"
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Richard Ronald

(Last)(First)(Middle)
300 PROFESSIONAL DR

(Street)
GAITHERSBURG MARYLAND 20879

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026A25,344(1)A$0123,761D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.9904/30/2026A11,296 (2)04/30/2033Common Stock11,296(3)$011,296D
Explanation of Responses:
1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
2. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
3. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Remarks:
/s/ Richard S. Lindahl, Attorney-in-fact05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did director Richard Ronald receive from Emergent BioSolutions (EBS)?

Director Richard Ronald received 25,344 restricted stock units and 11,296 stock options as board compensation. Each RSU converts into one common share upon vesting, and each option allows purchase of one share at a preset exercise price.

How many Emergent BioSolutions (EBS) RSUs were granted in this Form 4 filing?

The filing shows a grant of 25,344 restricted stock units to director Richard Ronald. These RSUs vest the day before the one-year anniversary of the grant date, contingent on his continued board service through that vesting date.

What are the terms of the stock options granted to the EBS director?

The director received 11,296 stock options, each to buy one Emergent BioSolutions common share at an exercise price of $7.99. The options vest on the same one-year schedule as the RSUs and expire in 2033 if not exercised.

When do the new Emergent BioSolutions (EBS) RSUs and options vest?

Both the RSUs and stock options vest on the day prior to the one-year anniversary of the grant date. Vesting requires that Richard Ronald remain a member of Emergent BioSolutions’ board of directors through that Annual Grant Vesting Date.

How many Emergent BioSolutions (EBS) shares does the director hold after these grants?

After the equity awards reported, Richard Ronald directly holds 123,761 shares of Emergent BioSolutions common stock. This total includes his existing holdings plus the newly granted RSUs, which represent rights to receive additional shares upon vesting.

How was the size of the Emergent BioSolutions (EBS) option grant determined?

The number of options, 11,296, was calculated by taking 25% of the total non-employee director compensation value and dividing that amount by the Black-Scholes value of a single option, measured as of the grant date under the company’s Stock Incentive Plan.